Life Technologies Chairman and CEO Gregory T. Lucier Named Penn State University Outstanding Engineering Alumnus
Published: Apr 05, 2013
UNIVERSITY PARK, Pa., April 5, 2013 /PRNewswire/ -- Gregory T. Lucier, Chairman and CEO of Life Technologies in Carlsbad, Calif, has been named an Outstanding Engineering Alumnus by the Penn State College of Engineering in recognition of his exceptional professional achievements.
Established in 1966, the award is the highest honor the College bestows on its alumni. Lucier will be honored during a ceremony at the Nittany Lion Inn in State College on April 9.
A 1986 graduate of Penn State with a bachelor's degree in industrial engineering, Lucier fosters a culture of excellence at Life Technologies, a global biotechnology company with a presence in more than 180 countries and had sales of $3.8 billion in 2012. Ranked 9th among the world's 50 most innovative companies, Life Technologies is a market leader in products and services that accelerate advancements in basic research and drug development, molecular diagnostics, 21st century forensics, regenerative science and agricultural research. Today, he applies his more than 25 years of strategic management experience in his endeavor to shape an era of personalized medicine in which researchers can efficiently read, write and edit DNA for humanity's benefit.
After completing his M.B.A. at Harvard Business School, Lucier served in a variety of leadership roles at General Electric (GE) Corporation, including president and CEO of GE Medical Systems Information Technologies. After joining Invitrogen Corporation in 2003, a leading supplier of life sciences research tools, he led the 2008 merger between the company and Applied Biosystems, a deal valued at more than $6.5 billion that formed Life Technologies Corporation. Today, Lucier is driven to change the face of healthcare and with a vision to see genomic-based medicine implemented to guide targeted treatments of human disease in the near future.
Lucier also serves on the Board of Directors at Synthetic Genomics, Inc., CareFusion Corporation, Rady Children's Hospital and the California Healthcare Institute.
SOURCE The Pennsylvania State University